Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25123324 | 1.00 | DDB1 (0.43) | DDB1CRBNIRAK4GSK3BPRKCG | |
| SCHEMBL29990767 | 0.88 | CRBN (0.50) | DDB1CRBNIRAK4 | |
| SCHEMBL25123219 | 0.88 | CRBN (0.50) | DDB1CRBNIRAK4 | |
| SCHEMBL27166407 | 0.87 | CRBN (0.39) | DDB1CRBNIRAK4GSK3BSTAT3 | |
| SCHEMBL25122889 | 0.82 | DDB1 (0.45) | DDB1CRBN | |
| SCHEMBL29347187 | 0.82 | DDB1 (0.44) | DDB1CRBNIRAK4GSK3BPRKCG | |
| SCHEMBL25123798 | 0.81 | DDB1 (0.49) | DDB1CRBNSTAT3 | |
| SCHEMBL22776794 | 0.81 | DDB1 (0.49) | DDB1CRBNSTAT3 | |
| SCHEMBL25123857 | 0.81 | DDB1 (0.49) | DDB1CRBNSTAT3 | |
| SCHEMBL23842302 | 0.81 | DDB1 (0.49) | DDB1CRBNSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |